The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy†
Abstract
Patients with advanced hepatitis C virus (HCV) are at risk of death and are candidates for liver transplantation. After transplantation, HCV recurs and may rapidly progress to cirrhosis and graft loss. Treatment is needed to prevent progression of disease and minimize recurrence after liver transplantation. We evaluated the effectiveness, tolerability, and outcome of a low accelerating dose regimen (LADR) of antiviral therapy in the treatment of patients with advanced HCV. One hundred twenty-four patients (male/female ratio 81:43; age range 37-71 years; 70% genotype 1) were treated with LADR. Sixty-three percent had clinical complications of cirrhosis (ascites, spontaneous bacterial peritonitis, varices, variceal hemorrhage, encephalopathy). The mean Child-Turcotte-Pugh (CTP) score was 7.4 +/- 2.3, and the mean MELD score was 11.0 +/- 3.7. Fifty-six patients were CTP class A, 45 were class B, and 23 were class C. Forty-six percent were HCV RNA-negative at end of treatment, and 24% were HCV RNA-negative at last follow-up. Sustained virological response (SVR) was 13% in patients infected with genotype 1 HCV and 50% in patients infected with non-1 genotypes (P < .0001). Non-1 genotype, CTP class A (genotype 1 only), and ability to tolerate full dose and duration of treatment (P < .0001) were predictors of SVR. Twelve of 15 patients who were HCV RNA-negative before transplantation remained HCV RNA-negative 6 months or more after transplantation. In conclusion, in a sizeable proportion of patients with advanced HCV, LADR may render blood free of HCV RNA, stabilize clinical course, and prevent posttransplantation recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J., et al. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024300 · Cited by 1,399
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C
Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M., & Hoofnagle, J. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212204 · Cited by 1,212
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,198
Alter, M. J. (1997) · Hepatology · doi:10.1002/hep.510260711 · Cited by 1,075
Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin
Kenny-Walsh, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401602 · Cited by 910
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis
Seeff, L. B., Buskell-Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272703 · Cited by 672
Burden of liver disease in the United States: Summary of a workshop
Kim, R. W., Brown, R. S., Terrault, N. A., & El-Serag, H. (2002) · Hepatology · doi:10.1053/jhep.2002.34734 · Cited by 589
Armstrong, G. L., Alter, M. J., McQuillan, G. M., & Margolis, H. S. (2000) · Hepatology · doi:10.1002/hep.510310332 · Cited by 523
Wiesner, R. H., Sorrell, M., & Villamil, F. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50268 · Cited by 442
Determinants of outcome of compensated hepatitis C virus-related cirrhosis
Serfaty, L., Aumaître, H., Chazouillères, O., Bonnand, A.-M., Rosmorduc, O., Poupon, R. E., & Poupon, R. Y. (1998) · Hepatology · doi:10.1002/hep.510270535 · Cited by 403
Wiese, M., Berr, F., Lafrenz, M., Porst, H., & Oesen, U. (2000) · Hepatology · doi:10.1053/jhep.2000.8169 · Cited by 349
Hu, K., & Tong, M. J. (1999) · Hepatology · doi:10.1002/hep.510290424 · Cited by 273
Natural history of hepatitis C
Seeff, L. B. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00374-5 · Cited by 239
Rodger, A. J., Roberts, S., Lanigan, A., Bowden, S., Brown, T., & Crofts, N. (2000) · Hepatology · doi:10.1053/jhep.2000.9714 · Cited by 182
Which patients with hepatitis C develop liver complications?
Khan, M. H., Farrell, G. C., Byth, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Kench, J., Kaba, S., Crewe, E., et al. (2000) · Hepatology · doi:10.1002/hep.510310236 · Cited by 160
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Natural history of hepatitis C.
Westbrook, R. H., & Dusheiko, G. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.012 · Cited by 1,049
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Berenguer, M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.05.002 · Cited by 342
Metadata
- Authors
- Everson, G. T., Trotter, J., Forman, L., Kugelmas, M., Halprin, A., Fey, B., & Ray, C.
- Venue
- Hepatology
- Published
- 2005-08
- Volume
- 42
- Issue
- 2
- Pages
- 255-262
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2069309210
- Cited by
- 357
- References
- 22
- FWCI
- 21.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.